Zanubrutinib

• CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies Recruiting
  2025-523600-68-00 Phase II 2 countries Curis Inc.
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting
  2025-524366-21-00 Phase III 9 countries BeOne Medicines I GmbH
• A Study of Zanubrutinib Versus Tacrolimus in Participants With Primary Membranous Nephropathy (ALMOND) Recruiting
  2022-501147-32-00 Phase II/III 4 countries BeOne Medicines AG
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 Phase III 14 countries BeOne Medicines AG
• A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting
  2024-515654-25-00 Phase I/II 2 countries Ascentage Pharma Group Inc.
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l… Recruiting
  2024-511267-28-00 Phase III 9 countries BeOne Medicines AG
• Zanubritnib and anti-MAG neuropathy Recruiting
  2025-523091-23-00 Phase II 1 country Azienda Ospedaliera di Padova
• A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting
  2024-516234-35-00 Phase I/II 3 countries BeOne Medicines AG
• A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Patients Treated for Blood Cancers Recruiting
  2024-518829-15-00 Phase I/II 1 country BeOne Medicines AG
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi… Recruiting
  2024-515593-27-00 Phase III 6 countries BeOne Medicines AG
• A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subj… Recruiting
  2023-506706-40-00 Phase II/III 2 countries Lymphoma Academic Research Organisation
• A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab i… Recruiting
  2023-504647-14-00 Phase II 1 country Pethema Fundacion
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting
  2023-508005-24-00 Phase III 11 countries Ascentage Pharma Group Inc.
• Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associate… Recruiting
  2023-505933-29-00 Phase II 1 country University Medical Center Utrecht
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-… Recruiting
  2023-510431-11-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS… Recruiting
  2023-504653-12-00 Phase II 3 countries University Of Cologne
• A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chroni… Ended
  2024-513970-23-00 Phase II 3 countries BeOne Medicines AG
• Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended
  2023-506049-52-00 Phase II 1 country Fondazione Italiana Linfomi Ets
• HOVON 169 CAD: Phase II trial of Zanubrutinib in primary Cold Agglutinin Disease. CaZa study Ended
  2023-505746-25-00 Phase II 4 countries Haemato Oncology Foundation For Adults Netherlands
• Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended
  2023-503755-10-00 Phase III 7 countries Association International Extranodal Lymphoma Study Group
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended
  2023-506948-17-00 Phase III 9 countries BeOne Medicines AG
• Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended
  2023-503235-18-00 Phase II 4 countries BeOne Medicines AG
• Evaluation of a treatment with bendamustine, followed by obinutuzumab, zanubrutinib and venetoclax in patients with relapsed chronic lymphoc… Ended
  2022-502201-16-00 Phase II 1 country University Of Cologne
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended
  2023-509908-15-00 Phase II/III 11 countries BeOne Medicines AG

Showing 1–24 of 26 trials